A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy
Jue Zhang(Foshan Hospital of TCM), Lizhu Lin(Guangzhou University of Chinese Medicine), Yuka Harata‐Lee(The University of Adelaide), Thazin Nwe Aung(Yale University), Le Xie(Nankai University), Zhipeng Qu(The University of Adelaide), Jian Cui(Beijing Chuiyangliu Hospital), Dongying He(Taiyuan University of Technology), Lingling Sun(Second Affiliated Hospital of Zhejiang University), Aisheng Wei(Foshan Hospital of TCM), Hong Yao(Foshan Hospital of TCM), Xi Xiao, David L. Adelson(South Australian Museum), Jing Li(Donghua University), Zijing Huang(Hainan University)
Cited by 1
Related Papers
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
|npj Precision Oncology|2024|535